| Past Issue | Volume 4, Number 3, 2002 | | Open Label, Prospective, Multicentre Indian Study of Latanoprost in Primary Open Angle Glaucoma and Ocular Hypertension |
Indian Latanoprost (Xalatan) Study Group
Dr Aditya Agarwal, Shakti Eye Hospital, Indore; Dr Nishita Agarwala, PD Hinduja National Hospital & Research Center, Mumbai; Dr Rekha Chandra, Telco Hospital, Jamshedpur; Dr GS Dhami, Dhami Eye Hospital, Ludhiana; Dr Rajat Dhesi, Prakash Netra Kendra, Lucknow; Dr Kulin Kothari, Bombay City Eye Institute, Mumbai; Dr Harbans Lal, Sir Ganga Ram Hospital, New Delhi; Dr Moniz Noel, CBM Ophthalmic Institute Little Flower Hospital, Angamally; Dr Praful Mokadam, Anjani Eye Hospital, Nagpur; Dr BK Nayak, PD Hinduja National Hospital & Research Center, Mumbai; Dr Paromita Sanatani, Athena Eye Care, Calcutta; Dr B Sridhar Rao, Kumaran Hospital, Chennai; Dr JS Thind, Thind Eye Hospital & Lasik Centre, Jalandhar; Dr Prateep Vyas, Ganapati Netralaya, Jalna.
Aims: To evaluate the intraocular pressure lowering effect and safety of latanoprost 0.005% in patients with primary open angle glaucoma and ocular hypertension.
Patients and Methods: 126 patients with primary open angle glaucoma or ocular hypertension were enrolled in this prospective open label study from 15 centres in India. Patients were treated with latanoprost 0.005% once daily as single therapy for 3 months.
Results: At all the follow-up visits there was a significant reduction in intraocular pressure compared with baseline values (p < 0.05). At 3 months (week 12), a mean intraocular pressure reduction of 9.1 ± 3.9 mm Hg was obtained. The most frequently reported adverse ocular events were mild congestion (4.2%) and itching (2.5%). Few systemic adverse events were reported.
Conclusion: Latanoprost eye drops showed a marked intraocular pressure lowering effect during the treatment period. The drug was well tolerated and the intraocular pressure lowering effect was stable during the treatment period
Asian J Ophthalmol 2002;4(3):2-5.
| | | |
|
